roferon-a 3 miu/0,5 ml
roche slovensko - interferón alfa-2a - 44 - cytostatica
roferon-a 9 miu/0,5 ml
roche slovensko - interferón alfa-2a - 44 - cytostatica
ihla pen fine ( pre roferon - pen)
roche diagnostics gmbh., kirchbergstrasse 190 ch-3401 burgdorf Švajčiarsko -
pero roferon - pen
roche diagnostics gmbh., kirchbergstrasse 190 ch-3401 burgdorf Švajčiarsko -
alpheon
biopartners gmbh - recombinant human interferon alfa-2a - hepatitída c, chronická - immunostimulants, - adult patients with histologically proven chronic hepatitis c who are positive for hepatitis c virus (hcv) antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation. the efficacy of interferon alfa-2a in the treatment of hepatitis c is enhanced when combined with ribavirin. alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.
pegasys
pharmaand gmbh - peginterferón alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 a 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. s ohľadom na rozhodnutie o začatí liečby v pediatrických pacientov pozri časť 4. 2, 4. 4 a 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 a 5. pre vírusom hepatitídy c (hcv) genotyp špecifické činnosti, pozri časť 4. 2 a 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. pri rozhodovaní o tom, na začatie liečby v detstve, je dôležité zvážiť, inhibícia rastu vyvolané kombinácia terapie. reverzibilita inhibícia rastu je neistá. rozhodnutie na liečbu by mala byť predložená na prípad (pozri časť 4.
iomeron 350
bracco imaging deutschland gmbh, nemecko - jomeprol - 48 - diagnostica
iomeron 150
bracco imaging deutschland gmbh, nemecko - jomeprol - 48 - diagnostica
iomeron 200
bracco imaging deutschland gmbh, nemecko - jomeprol - 48 - diagnostica
iomeron 250
bracco imaging deutschland gmbh, nemecko - jomeprol - 48 - diagnostica